GAMIDA CELL LTD.

Analyst Reco. Gamida Cell Ltd.

Equities

GMDA

IL0011552663

Delayed OTC Markets Other stock markets 01:32:44 2024-04-29 pm EDT			5-day change	1st Jan Change
0.017 ^USD	-7.61%		+3.03%	-95.88%

Apr. 10	Gamida Cell Ltd.(NasdaqGM:GMDA) dropped from S&P Global BMI Index	CI
Apr. 05	Gamida Cell Ltd.(OTCPK:GMDA.Q) dropped from NASDAQ Composite Index	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JMP Securities Downgrades Gamida Cell to Market Perform From Market Outperform	Jan. 29	MT
Piper Sandler Adjusts Gamida Cell's Price Target to $2 From $5, Maintains Overweight Rating	Nov. 15	MT
HC Wainwright Adjusts Price Target on Gamida Cell to $5 From $11, Keeps Buy Rating	Nov. 15	MT
JMP Securities Adjusts Price Target on Gamida Cell to $6 From $8, Keeps Market Outperform Rating	23-05-19	MT
Oppenheimer Adjusts Gamida Cell Price Target to $6 From $8, Maintains Outperform Rating	23-05-16	MT
Needham Lowers Price Target on Gamida Cell to $6 From $8, Maintains Buy Rating	23-04-20	MT
HC Wainwright Adjusts Price Target on Gamida Cell to $11 From $5, Keeps Buy Rating	23-04-19	MT
Oppenheimer Adjusts Gamida Cell Price Target to $8 From $10, Maintains Outperform Rating	23-03-28	MT
HC Wainwright Adjusts Price Target on Gamida Cell to $5 From $22, Maintains Buy Rating	23-03-28	MT
Needham Adjusts Price Target on Gamida Cell to $8 From $9, Maintains Buy Rating	22-11-22	MT
Oppenheimer Adjusts Gamida Cell PT to $10 From $15, Notes Uncertainty Around Ex-US Regulatory, Commercial Strategy; Maintains Outperform Rating	22-11-15	MT
Piper Sandler Adjusts Gamida Cell's Price Target to $7 From $8, Reiterates Overweight Rating	22-10-03	MT
Needham Adjusts Price Target on Gamida Cell to $12 from $14, Keeps Buy Rating	21-11-16	MT
Oppenheimer Adjusts Gamida Cell PT to $15 From $17, Maintains Outperform Rating	21-11-16	MT
RBC Cuts Price Target on Gamida Cell to $11 From $14, Citing Setback to Omidubicel Filing Timeline; Outperform-Speculative Risk Rating Kept	21-11-12	MT
GAMIDA CELL : RBC Capital Adjusts Gamida Cell PT to $14 From $12, Maintains Outperform - Speculative Risk	21-03-10	MT
GAMIDA CELL : Needham Adjusts Price Target on Gamida Cell to $14 From $17, Maintains Buy Rating	21-03-09	MT
GAMIDA CELL : Oppenheimer Adjusts Gamida Cell PT to $17 From $20, Maintains Outperform Rating	20-12-15	MT
GAMIDA CELL : RBC Capital Adjusts Gamida Cell's Price Target to $12 From $13, Maintains Outperform-Speculative Risk Rating	20-12-15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Rankings

More Top / Flop

Rankings

More Top / Flop

Currency / Forex

Commodities

Cryptocurrencies

Cryptocurrencies

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer